Seton Hall University

eRepository @ Seton Hall
Seton Hall University Dissertations and Theses
(ETDs)

Seton Hall University Dissertations and Theses

Spring 5-2013

Activation and Suppression of the Innate Immune
System: Effects on Alcohol Intake
Marjorie Levinstein
Seton Hall University

Follow this and additional works at: https://scholarship.shu.edu/dissertations
Part of the Health Psychology Commons, Neurosciences Commons, and the Other Psychology
Commons
Recommended Citation
Levinstein, Marjorie, "Activation and Suppression of the Innate Immune System: Effects on Alcohol Intake" (2013). Seton Hall
University Dissertations and Theses (ETDs). 1862.
https://scholarship.shu.edu/dissertations/1862

Activation and Suppression of the Innate Immune System: Effects on Alcohol Intake

by

Marjorie Levinstein

A thesis submitted in partial fulfillment of the requirements for the degree of

Master of Science in Experimental Psychology

with a concentration in Behavioral Neuroscience

Department of Psychology

Seton Hall University

May, 2013

Approved By:

Michael Vigorito, PhD., Faculty Mentor

Janine Buckner, PhD., Director of Graduate Studies

ii

Acknowledgements
I want to thank my advisor, Dr. Michael Vigorito, for his support and guidance
throughout the research process. I am grateful to Dr. Sulie L. Chang for providing naltrexone
for this study. I want to thank her and Dr. Amy S. Hunter for dedicating their time and insight
while serving on my thesis committee. I am indebted to Katherine Moen and Klaudia Kosiak for
their substantial help in data collection.

My time at Seton Hall University would not be the same without Dr. Susan Nolan and
Dr. Janine Buckner and the entire faculty and staff of the Department of Psychology. Their
support has helped me beyond words. Finally, I want to thank all of my friends and family;
who have supported me throughout my graduate education.

iii

\

Table of Contents
Approval Page ............................................................................................................................................... ii
Acknowledgements ...................................................................................................................................... iii
List of Figures ...............................................................................................................................................vi
List of Tables................................................................................................................................................vii
Abstract ......................................................................................................................................................viii

Introduction ..................................................................................................................................................1
Basic Functions of the Immune System ...................................................................................................1
Innate and adaptive immunity.............................................................................................................3
Toll-like receptors.................................................................................................................................4
Purpose of the Current Experiment .........................................................................................................6
Method .......................................................................................................................................................10
Subjects ...................................................................................................................................................10
Drugs .......................................................................................................................................................10
Naltrexone Treatment ........................................................................................................................10
LPS Treatment .....................................................................................................................................11
Procedure ................................................................................................................................................11
Initial training in the test cages ..........................................................................................................11
Home cage (24 hr) exposure to ethanol (EtOH) ................................................................................12
Short term EtOH preference tests .....................................................................................................13
Data Analysis ...........................................................................................................................................14
Results .........................................................................................................................................................15
Immediate LPS effectiveness .................................................................................................................15
Weight-change after LPS injection .....................................................................................................15
Weight recovery after LPS injection...................................................................................................16
Home cage EtOH consumption ..............................................................................................................17
Phase 1 Continuous EtOH Access - EtOH preference ........................................................................17

I

Phase 1 Continuous EtOH Access - EtOH grams consumed ..............................................................18
Phase 2 Intermittent EtOH Access - EtOH preference .......................................................................19
Phase 2 Intermittent EtOH Access - EtOH grams consumed .............................................................21
Individual short-term two-bottle preference tests ...............................................................................22

iv

\

I

Polycose preference ...........................................................................................................................22
EtOH preference .................................................................................................................................23
EtOH grams consumed .......................................................................................................................24
Discussion ...................................................................................................................................................26
References ..................................................................................................................................................34

v

r

\

I

j

I
I
I
I
ff

I

J
J

list of Figures
Figure 1. Bodyweight changes before and after lPS injection .................................................................... 15
Figure 2. Bodyweight change in days following lPS injection .....................................................................17
Figure 3. Preference for EtOH bottle during phase 1.................................................................................. 18
Figure 4. Grams of EtOH consumed during Phase 1 ................................................................................... 19
Figure 5. Preference for EtOH bottle during Phase 2 .................................................................................. 20
Figure 6. Grams of EtOH consumed during Phase 2 ................................................................................... 22
Figure 7. Preference for the bottle containing Polycose ............................................................................23
Figure 8. Preference for the bottle containing EtOH during individual tests .............................................. 24
Figure 9. Grams of EtOH consumed during individual tests .......................................................................25

I
i
~

i

Ii

vi

List of Tables
Table 1. Procedural Timeline .......................................................................................................................13

vii

I

Abstract
Prior research indicates that immune system activation with a single dose of the bacterial toxin
lipopolysaccharides (LPS) causes increased ethanol (EtOH) intake in rodents even three months
after an injection. This result suggests that immune system activation may induce a long-term
change in behavior. Naltrexone is known to be a partial antagonist on the same toll-like
receptors of immune cells that are targeted by LPS. This drug presumably would nullify the LPS
effect. In this study, we attempted to replicate the LPS-induced increase in EtOH consumption
in rats and investigated the impact of repeated naltrexone treatment on the effects of LPS on
subsequent EtOH intake. The animals received one injection of LPS (or saline). For two weeks
before and two weeks after LPS treatment, the animals received daily naltrexone or saline
injections. LPS did not reliably increase EtOH intake as in previous studies, therefore an
intermittent drinking schedule was introduced to further increase drinking rates in all groups.
Interestingly, the results of the intermittent home-cage exposure to EtOH and subsequent
individual short-term preference tests indicate that the LPS and naltrexone have an additive
effect as the group with both treatments drank the most EtOH.
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Activation and Suppression of the Innate Immune System: Effects on Alcohol Intake

Recently, the interplay between the immune and nervous systems has been of great
interest to researchers. The role of the immune system on behavior is larger than previously
imagined. Neuroimmune pharmacology is a young field created as a convergence of
neuroscience, immunology and pharmacology (Freilich & Izeku, 2011). The immune system is
implicated in many neurological and psychiatric diseases such as autoimmune diseases ofthe
brain, neurodegenerative disorders, mood disorders, and drug abuse (Freilich & Izeku, 2011). It
seems likely that the introduction of, and subsequent immune response to, one foreign body
(e.g. microbes) will affect the response to another foreign body (e.g. alcohol). Because of the
relationship to the nervous system, this response may have behavioral implications. In order to
better understand the interplay between the nervous system and the immune system, it is
helpful to describe some of the basic functions of the immune system.

Basic Functions of the Immune System

There are several components to the immune system, but the one most relevant to the
current discussion is the role of the immune system in identifying foreign particles entering the
cells of the body (cell-mediated immunity). The cells of the immune system that play this role
are called T cells or T lymphocytes. The T cells destroy the microbes themselves or individual
cells infected with the microbes. How does a T- cell know that a cell is infected with a microbe?
For this cell-mediated immunity to work it is necessary for a piece of the foreign protein on the
surface of the microbe (i.e., the antigen) to be removed and inserted into the outer membrane
of the infected cell itself. The infected cell can then be recognized by T cells for destruction.
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Normal T cells are naive and need to be informed that the microbes are present in the body;
that is they need to be induced and mobilized with other cells for an efficient attack. Several
cell types in the class of cells called antigen-presenting cells (APC) have the task of quickly

,
,,

notifying the T cells of the presence of the microbes. An APC captures the invading microbe and
after inserting the antigen into its own surface membrane it travels to the lymphoid organs

ij

where it presents the antigen to the naive T cells to induce an immune response. Some T cells

1

do the killing and some help with the mobilization. The T cells that do the killing of infected

1

cells are Cytotoxic T cells. There are also Helper T cells which when presented with an antigen

l,

I,

from an APC release signals (small proteins called cytokines) to mobilize the T cells and several
other cells (e.g., macrophages & B lymphocytes) for an effective defensive action (Abbas &
Lichtman, 2005).

Beta-2-microglobulin (B2m) is a protein in the class of molecules called major
histocompatibility complex (MHC). MHC molecules are found on every cell of the body with
nuclei (not red blood cells and platelets because they do not have nuclei). MHC is necessary for
APC to present the antigen to Cytotoxic T cells because T cells can only recognize foreign
protein fragments that have been bound to MHC molecules. By knocking out the B2m gene the
MHC - antigen complex is disrupted, so the Cytotoxic T cells do not "see" the infected cells
(Abbas & lichtman, 2005).

Cathepsin S (CTSS) is an enzyme found in Iysosomes that breaks down other proteins (a
protease). CTSS helps create the antigen by breaking down a protein from the foreign microbe
that can be incorporated in the MHC of APe. Without the ability to create this protein fragment
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an antigen cannot be presented to the Cytotoxic T cells for induction of an immune response.
Cathepsin F (CTSF) is another lysosomal protease with similar functions as the other cathepsins
(Abbas & Lichtman, 2005).

Interleukin 1 receptor antagonist (II-lra) is a cytokine. A cytokine is a small protein that
immune cells secrete to communicate with each other (essentially a hormonal communication
system for immune cells). The Helper T cells release cytokines to mobilize the immune
response. Examples of cytokine classes are the interleukins and the interferons. A member of
the interleukin cytokines is

Interleukin-l (IL-l). IL-l (there are an alpha and beta versions) is

responsible for the production of inflammation and fever, so it is classified as a pro

inflammatory cytokine (there are also anti-inflammatory cytokines). It is primarily the
macrophages that release IL-l. The IL-lra therefore antagonizes the pro-inflammatory effects
of IL-l and most likely is involved in regulating the effects of IL-l. Therefore by knocking out
the gene for IL-lra the regulation of IL-l is most likely disrupted. Interleukin 6 (lL-6) is a
cytokine that has both pro-inflammatory and anti-inflammatory properties. IL-6 is released by T
cells and macrophages. IL-6 also plays an important role in producing and regulating fever
(Abbas & Lichtman, 2005).

Innate and adaptive immunity. The body's cell-mediated defense against microbes
described so far is called

adaptive immunity and it is contrasted with innate immunity.

Adaptive immunity occurs in response to infection and adapts (hence the name) to repeated
infection by increasing in magnitude and by improving its defensive capabilities with
subsequent infections by mechanisms not discussed here. Innate immunity is the immediate
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defensive reaction to microbes even before infection has set in (i.e., the first line of defense).
Even if the infection repeats, the innate immune response does not change; it is always the
same in magnitude and in its defensive capability. While innate immunity evolved first and only
reacts to microbes, adaptive immunity evolved later and reacts to microbes as well as non
microbial substances (e.g., cancer cells). It is the adaptive immune system that is the likely
culprit in autoimmune diseases, for example. Therefore it would seem that the effect of LPS on
EtOH consumption would be mediated through effects on innate immunity rather than
adaptive immunity. However, the innate and adaptive immune responses have evolved into a
bi-directional integrative defensive system. One of the strategies of the adaptive immune
system to combat microbes is to activate and enhance the innate immune response (for
example, when Helper T cells release cytokines to activate phagocytes). Also while the innate
immune response provides the first defensive response to microbes it also serves as a
"warning" to activate the adaptive immune response which then prepares for possible
subsequent infections. Therefore although LPS directly activates the innate immune system, it
also indirectly affects the adaptive immune response which in turn may affect the nervous
system and subsequent behavior (Abbas & Lichtman, 2005).

Toll-like receptors. The C014 molecule is a receptor protein that is expressed in the cells of the
innate immune system that identifies microbial pathogens. It is this receptor that binds with
(and therefore identifies) the LPS molecule located on the surface of bacteria. However, the

C014 receptor cannot work alone, it is really a co-receptor. To detect LPS the CO 14 receptor
must be activated as well as the Toll-like receptor TLR 4 and the MD2 receptor. A CD 14
knockout mouse would be missing one of the co-receptors so it would not be able to detect LPS
4

and therefore an innate immune response to bacteria would not occur and the adaptive
immune response would not be activated (Abbas & Lichtman, 2005).

In previous studies, researchers activated the immune system of rodents using
lipopolysaccharides (lPS) and observed changes in subsequent ethanol (EtOH) consumption
(Bled nov et aI., 2011; Casachahua, 2011). lPS are large molecules found on the outside of gram
negative bacterial cells and are recognized by the immune system (Raetz & Whitfield, 2002;
Rosenfeld & Shai, 2006). The immune system activates in the presence of lPS alone (Rosenfeld

& Shai, 2006). Creating an immune response in this manner is preferable to bacterial infection
because there is no actual infection, merely an immune response as though there was one.

Blednov and colleagues (2011) performed one intraperitoneal injection of lPS (1 mg/kg)
in EtOH-preferring mice, and after allowing a recovery period, tested EtOH preference. Using a
two-bottle test, they slowly increased the percentage of EtOH in one of the bottles. The mice
that had been injected with lPS preferred EtOH significantly more than the controls. This effect
was seen even three months after the single dose of lPS, indicating that immune system
activation had long term influence on later behavior. Casachahua (2011) attempted to replicate
this finding using long-Evans rats in order to see if the effect observed in mice also occurs in
rats; however, he also included a measure of sign-tracking bottles containing EtOH. Although no
effect of lPS treatment was found on the sign tracking of EtOH, like the previous study with
mice, he found an increase in EtOH preference in the rats that had been injected with lPS. As
with Blednov and colleagues (2011), Casachahua (2011) found that this effect lasted for several
months after the injection.

5

The previous studies indicated that activating the immune system increases voluntary
EtOH intake. More recent research has also shown that a depressed immune system leads to
lowered EtOH intake. Blednov et al (2012) tested 6 different immune knockout mice. The
knock-out technique is a procedure used in molecular biology that target specific genes and
remove them to create a new strain. The mice used by Blednov et al had beta-2-microglobulin,
cathepsin 5, cathepsin F, interleukin 1 receptor antagonist, C014, or interleukin 6 genes
knocked out. All of these genes playa large role in immune system activation and function (see
below). They then gave the mice three tests - a 24-hour two bottle test, a limited access two
bottle test (present for 3 hours during the dark cycle), and limited access to EtOH only (2-4
hours during the light cycle). The authors found that knockout mice preferred EtOH less in the
24-hour two bottle test than did the non-knockout mice. The other tests showed differences in
preference for specific gene knock outs. There were no consumption differences of saccharin or
quinine, revealing that the immune system gene knockouts affected EtOH drinking specifically,
and not drinking behavior in general. These immune knockout mice provide compelling
evidence that the immune system is integrally involved in EtOH consumption.

Purpose of the Current Experiment

I

The current experiment serves several purposes. The first is to attempt to replicate the
findings of Casachahua (2011) and Blednov and colleagues (2011) that indicate LP5 increases
EtOH intake in rodents. The second goal of this study is to determine if blocking the Toll-Like
receptor 4 with naltrexone will moderate this effect either partially or completely.

6
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The method of this experiment aligns with those used in previous studies. Rats were
injected with LPS in order to create an innate immune response. They were then tested with a
24·hour two bottle choice test with a gradual increase in EtOH percentage. Since the animals
were caged in pairs, a limited two bottle choice test for the individual rats was added. However,
in order to subdue the immune system response in some rats without completely knocking out
any of the co·receptors needed to detect LPS, pre· and post· treatment of naltrexone was used.
Interestingly, recent studies indicate that some drugs long known to act as competitive
antagonists of opioid receptors also block the TLR4 receptor (Hutchinson et aI., 2010).
Naltrexone is a competitive antagonist of the .,a- and

K-

opioid receptors (Lee et aI., 1988) and,

like the related drug naloxone, appears to block the TLR 4 receptor (Hutchinson et aI., 2008).

However, there are some potential confounds when using naltrexone in this study that
were worked around. The first is that the drug reduces the palatability of many different
substances. By measuring facial responses to different tastes, Ferraro III, Hill, Kaczmarek,
Coonfield and Kiefer (2002) found that naltrexone created more aversive reactions to sucrose,
sodium chloride, quinine, and EtOH. In fact many studies have found that naltrexone reduces
palatability and intake of EtOH, even at low doses (Parkes & Sinclair, 2000; Lankford & Myers,
1996; Zalewska·Kaszbuska, Gorska, Oyr & Czamecka, 2008; Coonfield et aI., 2002). If the rats do
not like the taste of EtOH because of naltrexone's properties, then they will not drink it for that
reason, not because ofthe suppression oftheir immune system.

Naltrexone also reduces caloric intake in general. In both human and rat studies,
participants given naltrexone ate less especially if previously given access to the substance

l
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(Kanarek, Mathes, Heisler, Lima & Monfared, 1997; MacDonald, Billington & Levine, 2003;
Yeomans & Gray, 1996; Yeomans & Gray 1997; Lowy & Yim, 1981). Human participants found
that their appetite was smaller and their enjoyment of food was reduced when taking
naltrexone. These participants also ate significantly less than the placebo group (Yeomans &
Gray, 1996; Yeomans & Gray, 1997). However, one study found that naltrexone treated rats
had higher food intake; this may be an anomaly though (De Tomasi & Juarez, 2011). Since EtOH
has a high caloric content, if naltrexone causes loss of appetite and decreased caloric intake,
then reduced consumption of EtOH may not be caused by immune system suppression.

Possibly of the most concern is that naltrexone is used as a treatment for alcoholism. In
fact, that is one of its main clinical uses. Since naltrexone decreases EtOH intake presumably
because of competitive antagonism through the actions on opiate neurons, then using the drug
to study EtOH intake caused by altered immune function could complicate interpretation of the
results.

The potential confounding effects of naltrexone are either co-extensive with the
administration of the drug or terminate shortly after its last administration (Kanarek et aI.,
1997; MacDonald, Billington & Levine, 2003; Yeomans & Gray, 1996; Yeomans & Gray 1997;
Lowy & Yim, 1981; Parkes & Sinclair, 2000; Lankford & Myers, 1996; Zalewska-Kaszbuska et aI.,
2008; Coonfield et at, 2002; Ferrero III et aI., 2002). This is the key to avoiding those effects.
Naltrexone was given in this experiment for two weeks before and after LPS treatment but not
during the subsequent part of the experiment when the rats are drinking EtOH. The TLR4
receptor should be occupied by the naltrexone before the LPS injection, so that the immediate
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immune activation is reduced. Naltrexone, however, has a fairly short half-life in the body.
While naltrexone may be effective in humans for as long as 108 hours after ingestion, rats have
a higher metabolism rate of the chemical (Lee et aI., 1988). Gonzalez and Brogden (1988) found
that the half-life in rats was only between 2.7 and 3.7 hours after injection. Therefore while we
were unable to block the Toll-like receptor during the entire period of exposure to LPS it is of
interest to determine if a chronic, but partial blockage of TLR4 receptors reduces LPS-induced
increase in EtOH consumption. At least one study reported that daily pretreatment with the
opiate antagonist naloxone reduced the inflammatory effects of LPS (Le. naloxone had antiinflammatory effects) (Liu et al., 2002).

As discussed earlier, naltrexone decreases EtOH consumption in a variety of ways.
However, naltrexone is not needed once the LPS is out of the rats' bodies. Therefore,
naltrexone was discontinued before EtOH preference testing began. Since naltrexone has such
a short half-life in the rat, there should be no naltrexone affecting the study once it preference
testing began. Thus, any observed effects of naltrexone treatment on subsequent EtOH
consumption will have been a result of long-lasting effects on the cells of immune or neural

f

systems with receptors targeted by naltrexone.

)
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Method
Subjects
The subjects were 30 male, approximately 40 days old, Long Evans rats from Harlan
Laboratories, Inc. (Indianapolis), raised in pairs within shoebox cages. These rats were given
food and water ad libitum and were maintained on a 12 hour light-dark cycle, with the light
turning on at 8 am. Forty-six days after the beginning of this experiment, one of the rats had to
be separated from his cage-mate because of sudden weight-loss, mostly likely resulting from
aggressive dominance from its cage mate. He subsequently regained weight and his data have
been included. This experiment was approved by Seton Hall University's Institutional Animal
Care and Use Committee. All guidelines for the care and use of rats set by the United States
Public Health Service have been firmly followed.
Drugs
Naltrexone Treatment. Fourteen days prior to and twelve days after the LPS injection,
16 rats were injected intra peritoneally (IP) with 5.0 (first six days) to 7.0 (remaining twenty
days) mg/kg of naltrexone (from Sigma Aldrich, St. Louis, MO) dissolved in saline, while the
other 14 were injected with the equivalent amount of saline every day at the same time
(approximately 12 PM). Naltrexone dosing varies greatly in the literature. Chronic or repeated
naltrexone doses vary from 1.0 mg/kg/day to 10 mg/kg/day (Sanchis-Segura, Pastor & Aragon,
2004; De Tomasi & Juarez, 2011). Therefore, we used a middle dose of 5mg/kg/day. The lower
dose was used initially to make sure that naltrexone did not disrupt normal eating and drinking
and was increased to 7mg/kg/day dose for the remainder of treatment when the data
confirmed that feeding and drinking remained at normal levels.

10

LPS Treatment. After an initial phase of training to drink in test cages (see procedure)
and after 2 weeks of daily treatment with naltrexone or saline, 16 rats (8 treated with
Naltrexone, and 8 treated with saline) were injected IP with 1.0 ml/mg/kg of LPS (from
Salmonella enterica, Cat#l65 11, Sigma, St. Louis, MO) dissolved in saline, while the other 14
rats (8 treated with Naltrexone, and 6 treated with saline) were injected with the equivalent
amount of saline. These groups were equated in terms of body weight and how much they
drank during the training in the test cages. lPS treatment induces malaise and elevated body
temperature lasting up to 24 hrs, thus injections were aligned with rat pairing (i.e., each cage
mate received the same injection treatment). This injection occurred immediately after the
naltrexone injection that day. The rats were given nineteen days of recovery time prior to the
introduction of EtOH solution. Additionally, rat bodyweights were recorded from two weeks
prior to injection and the following 15 days. The behavior of the rats was monitored for
indications of malaise as well as body weight changes to confirm that there was a response to
lPS.
Procedure
rhe timeline of the procedure is listed in Table 1.
Initial training in the test cages. In order for the rats to learn to drink in the individual
tests later in the experiment, they were trained using Polycose solutions. Prior to the lPS
injection, the rats were adapted to suspended stainless steel mesh cages (20.3 cm x 20.3 cm x
22.9 cm) and trained to drink in these test cages. They were placed in the cages for 20 minutes
a day for four consecutive days and given a highly preferred Polycose {8%} solution in one
bottle and water in another (the bottles consist of 100 ml plastic graduated cylinders). The

11

position of the bottles was alternated each day. The intakes were determined by weighing the
bottles before and after the test session. As the time between this training and the short term
EtOH preference tests was several months, reminder training sessions were given roughly four
weeks before these EtOH preference tests were administered. For the reminder sessions, a 4%
Polycose solution was used. These cages were also used for short-term preference tests for
EtOH after EtOH was introduced in the home cage.
Home cage (24 hr) exposure to ethanol (EtOH). Beginning twenty days after the lPS
injection, each cage had both EtOH and water bottles present at all times in the home cages.
The EtOH bottle began at 1% and was increased gradually by 2% with at least 2 days at each
concentration up to 13% (as per Blednov et ai, 2011). However, at 7% EtOH concentration, all
groups suddenly decreased in EtOH preference. The preference did not recover when the
concentration was decreased. Previous studies indicated that EtOH intake in rodents can be
increased if EtOH is provided on the home cages intermittently (Rosenwasser et aI., 2012).
Three-day-a-week intermittent EtOH availability was then introduced. The EtOH bottle was
introduced Monday, Wednesday, and Friday at approximately noon and removed Tuesday,
Thursday, and Saturday at approximately noon. EtOH preference increased with this schedule
and the gradual increase of concentration was resumed. Preference began to decline at 13%
EtOH, so the concentration was kept at this level for the remainder of the experiment while the
rats were given individual short-term two-bottle preference tests. The position of both bottles
was switched each day to account for location preference. The consumption from both bottles
in each cage were measured daily by weighing each bottle.
.

f
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Short term EtOH preference tests. Although the rats sharing a cage were in the same
LPS (LPS or saline) and naltrexone (naltrexone or saline) conditions, it was not possible to know
the amount of EtOH consumed by the individual rats. Therefore twice a week, each animal was
tested individually for their EtOH preference in the test cages after the concentration in the
home cages was maintained at 13%. Each animal was placed in test cages with water and 5%
18% EtOH concentration presented in two bottles for 20 minutes, after which the bottles were
weighed to determine the quantity of EtOH consumed. The bottle location was switched the
next test day. These tests took place after the rats had not had access to EtOH for 24 hours.
Each concentration of EtOH (5%, 8%, 12%, 15%, and 18%) was tested twice to account for
possible side preference. This range of concentrations allowed for a better estimation of each
animal's consumption of, and preference for, EtOH.

Table 1. Procedural Tlmeline
Experimental Day(s)
1-4

Procedure
Polycose (8%) training sessions

3-8

Naltrexone (5mg/kg) or saline daily IP injections

9-28

Naltrexone (7mg/kg) or saline daily IP injections

17

LPS (1mg/kg) IP injection
24/7 home-cage access to EtOH (1%-7%) (Phase 1)

SO-51; 57-58

Polycose (4%) training sessions

58-123

3-day-a-week home-cage intermittent EtOH availability (5%-13%) (Phase 2)

86 and 88

Short-term individual tests at 5% EtOH

93 and 98

Short-term individual tests at 8% EtOH

13
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102 and 107

Short-term individual tests at 12% EtOH

114 and 116

Short-term individual tests at 15% EtOH

121 and 123

Shot-term individual tests at 18% EtOH

Data Analysis

Bodyweight, EtOH preference, and EtOH intake in grams were the main dependent
variables of interest. The bodyweight data were analyzed only on the LPS groups. Two mixed
design ANOVAs were used to analyze the data. The data for the before and after LPS were
analyzed with a naltrexone (Yes or No) x days (3) mixed methods ANOVA using the average of
the 3 days prior to LPS administration as the before group. The data for the recovery from LPS
were analyzed with a naltrexone (Yes or No) x days (4) mixed methods ANOVA. Naltrexone was
used as the between groups factor days as the within groups factor. The primary independent
variables for each of the EtOH and Polycose intake tests were naltrexone treatment, LPS
treatment, and concentration. Naltrexone treatment and LPS treatment were the betweengroups factors. Concentration was the within-groups factor.

14

Results

Immediate LPS effectiveness

Weight-change after LPS injection. Figure 1 shows body weight change after treatment
with LPS compared to the average bodyweight of the three days prior to the LPS injection. A
mixed two way ANOVA revealed a significant main effect for days, F(2,28}=18.271, p<.001,
.,2=.566. Post-hoc Bonferroni-corrected paired-samples t-tests revealed that the animals
weighed significantly more the three days prior to the injection {M=286.75, SD=3.86} than the
day after {M=274.75, SD=3.69}, t(15)=5.07, p=.001, and two days after (M=273.438, SD=4.18)
the injection, t(15)=4.41, p=.002. and two days after (M=273.438, SD=4.18) the injection. There
was no effect of naltrexone, F(1,14)=.043, p=.839, .,2=.008.
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Figure 1. Bodyweight changes before and after LPS injection
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Weight recovery after LPS injection. The mean bodyweights for the first four days after
the LPS injection are shown in Figure 2. A significant main effect of days, F(2,28)=24.763,

p<.OOl, 11 2=.740, confirmed that body weights were recovering. However, a Day (4) x Drug
treatment (naltrexone or saline) mixed ANOVA revealed a significant Day X Naltrexone
2

interaction, F(3,42)=3.41, p=.026, 11 =.196, indicating that the naltrexone-treated animals
showed a greater recovery of body weight following LPS treatment compared to saline-treated
controls. Post-hoc Bonferroni-corrected dependent-samples t-tests revealed that the rats
treated with naltrexone weighed significantly more on the third day after LPS treatment
compared to the first day, t(7)=8.142, p<.OOl, but the rats treated with saline did not,
t(7)=1.568, p=.161. However, an independent-samples t-test revealed that the naltrexone and
saline groups were not significantly different from each other by five days after the LPS
injection, t(14)=.727, p=.479.

16
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Home cage EtOH consumption

Phase 1 Continuous EtOH Access ~ EtOH preference. Preference scores were calculated
by dividing the grams of liquid consumed from the EtOH bottle by the total grams of liquid
consumed in both the EtOH bottle and the water bottle and multiplying by 100. As can be seen
in Figure 3, all groups consumed more EtOH than water at the two lowest EtOH concentrations,
but this preference was no longer present at the 7% concentration for any group. A mixed
2(Naltrexone: Yes, No) x 2(LPS: Yes, No} x 4(Concentration: 1%,3%,5%, 7%) ANOVA was
performed on the percent preference for EtOH. This ANOVA revealed a significant main effect
for concentration, F(3,33)=16.22, p<.001, .,2=.596. Post-hoc Bonferroni-corrected pairedsamples t-tests revealed that the preference for 7% (M=43.74, SD=23.97) was significantly less
than for 1% (M=77.78, SD=11.94), t{14}=-4.65, p<.OOl, 3% (M=81.05, SD=8.58), t(14}=-6.29,
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p<.OOl, and 5% (M=70.97, 50=22.57), t(14)=4.17, p=.OOl. These tests also revealed that the

preference for 3% was more than for 5%, t(14)=2.12, p=.052, but this was merely a trend. There
was no Naltrexone X LPS X Concentration interaction, F(3, 33}=.465, p=.709. All other
interactions also failed to be significant .
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Figure 3. Preference for EtOH bottle during phase 1

Phase 1 Continuous EtOH Access· EtOH grams consumed. Grams of EtOH consumed
were calculated by multiplying the grams of liquid consumed from the EtOH bottle by the
weight of EtOH per gram at each concentration (Figure 4). A mixed 2{Naltrexone: Yes, No) x
2(LPS: Yes, No) x 4{Concentration: 1%,3%,5%, 7%} ANOVA was performed on the grams of
EtOH consumed by the animals. This ANOVA revealed a significant main effect for
concentration, F{3,33)=21.25, p<.001, .,2=.659. Post-hoc Bonferroni-corrected paired-samples ttests revealed that the grams consumed at 1% (M=.47, 50=.07) was significantly less than for
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3% (M=1.54, 50=.18), t(14)=-26.57, p<.001, 5% (M=2.08, 50=.72), t(14}=-9.81, p<.001, and 7%
(M=1.79, 50=.99), t(14)=-5.03, p<.001. These tests also revealed that the grams consumed at

3% was significantly less than at 5%, t(14)=-3.26, p=.006. 'rhere was no Naltrexone X LPS X
Concentration interaction, F(3, 33)=.142, p=.934.
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Figure 4. Grams of EtOH consumed during Phase 1

Phase 2 Intermittent EtOH Access - EtOH preference. Because the consumption of EtOH
consumption dropped unexpectedly at the 7% EtOH concentration, an intermittent schedule of
EtOH was introduced to induce greater EtOH consumption in the home cages. As can be seen in
Figure 5, preference for EtOH generally increased at all but the highest concentration. A mixed
2(Naltrexone: Yes, No} x 2 (LPS: Yes, No) x 5 (Concentration: 5%, 7%, 9%, 11%, 13%) ANOVA was
performed on the percent preference scores. This ANOVA revealed a significant main effect for
2

concentration, F(4,48)=16.22, p<.001, 11 =.642. Post-hoc Bonferroni-corrected paired-samples
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t-tests revealed that the preference for 13% (M=50.22, 50=14.77) was significantly less than for
5% (M=66.88, 50=20.77), t(15)=-3.13, p=.007, 7% (M=81.41, 50=8.99), t(15)=9.08, p<.OOl, and
9% (M=68.88, 5D=16.97), t(15)=5.56, p<.OOl, and 11% (M=64.32, 50=12.88), t(15)=7.34, p<.001.

These tests also revealed that the preference for 7% was significantly more than for 5%,
t(15)=3.697, p=.002, 9%, t(15)=4.82, p<.OOl, and 11%, t(15)=7.195, p<.OOl. Additionally, the

preference for 9% was significantly more than for 11%, t(15)=2.35, p=.033. Further, there is a
trend of a concentration x naltrexone interaction, F(4,48)=2.37, p<.066, 11 2=.165, suggesting
that naltrexone had a tendency to increase preference for EtOH at the highest EtOH
concentrations. This naltrexone effect appears to have been mostly due to the Nal/lPS group,
however the Naltrexone X lPS X Concentration interaction failed to reach statistical
significance, F(4, 48) =.176, p=.950. No other interactions were significant.
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Figure 5. Preference for EtOH bottle during Phase 2

20

13%

Phase 2 Intermittent EtOH Access - EtOH grams consumed. Figure 6 replots the
preference data in terms of the mean grams of EtOH consumed. A mixed 2 (Naltrexone: Yes,
No) x 2 (LPS: Yes, No) x 5 (Concentration: 5%, 7%,9%, 11%, 13%) ANOVA was performed on the
grams of EtOH consumed. This ANOVA revealed a significant Naltrexone x LPS x Concentration
2

interaction, F(4,48)=2.63, p=.045, 11 =.180. Additional 2 (Naltrexone: Yes, No) x 2 (LPS: Yes, No)
between-groups ANOVAs were conducted on each EtOH concentration to identify the nature of
the interaction. Significant naltrexone x LPS interactions occurred at 7%, F(l, 12)=4.73, p=.050,
2

2

11 =.283,11%, F(l,12)=5.12, p=.043, 11 2=.298, and 13%, F(1,12)=10.75, p=.007, 11 =.472. Pairwise
comparisons reveal that at 7%, the Nal/LPS group (M=3.98, 50=.90) consumed significantly
more grams of EtOH than the Nal/Sal group (M=2.74, 50=.65) (mean difference = 1.23, p=.044).
However, Sal/Sal group (M=4.25, 50=.73) consumed more than the Nal/Sal group (M=2.74,

50=.65) (mean difference = 1.50, p=.027). The interaction at 9% was trending towards
2

significance, F(1,12)=3.55, p=.084, 11 =.228. Pairwise comparisons reveal that the Nal/LPS group

(M=4.75, 50=1.52) consumed more grams of EtOH than the Nal/Sal group (M=2.93, 50=.77)
(mean difference = 1.82, p=.047). Pairwise comparisons reveal that at 11%, the Nal/LPS group

(M=5.69, 50=1.32) consumed significantly more grams of EtOH than the Nal/Sal group (M=3.56,
50=.47) (mean difference = 2.12, p=.012). There is also a trend that the Nal/Sal group (M=5.69,
50=1.32) consumed more EtOH than the Sal/LPS group (M=4.32, 50=1.13) (mean difference =
1.36, p=.096). Pairwise comparisons reveal that at 13%, the Nal/LPS group {M=5.28, 50=1.53}
consumed significantly more grams of EtOH than the Nal/Sal group (M=2.55, 50=.62) (mean
difference = 2.73, p=.OOl). Additionally, the Nal/LPS group (M=5.28, 50=1.53) consumed more
than the Sal/LPS group (M=2.99, 50=.75) (mean difference = 2.29, p=.007). A significant
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Naltrexone x Concentration interaction was also revealed J F(4A8)=3.15 J p=.022. AdditionallYJ a
significant main effect for concentration was found J F{4A8)=40.08J p<.OOl.
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Figure 6. Grams of EtOH consumed during Phase 2

Individual short-term two-bottle preference tests.

Polycose preference. Before initiating preference tests with EtOH J all groups were
trained with two concentrations of Polycose versus water. A 2 (Naltrexone: Yes J No) x 2 (LPS:
YesJ No) x 2 (Concentration: 4%J 8%) mixed ANOVA was performed on percent preference for

Polycose. A significant Naltrexone X Concentration interaction was revealed J F(l J 26)=6.023 J
p=.021J ,,2=.188. Post-hoc independent-samples t-tests revealed a trend that the naltrexone

animals preferred the 8% Polycose solution less than the 4% solution, t(15)=-2.11 J p=.052 J
whereas J the saline group did not differ in preference, t(15)=1.312 J p=.212. HoweverJ post-hoc
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analyses did not reveal significant group differences. "rhere was no Naltrexone X LPS X
Concentration interaction, F(1,26)=1.82, p=.189.
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Figure 7. Preference for the bottle containing Polycose

EtOH preference. A mixed 2 (Naltrexone: yes, no) x 2 (lPS: yes, no) x 3 (Concentration:
5%,8%, and 12%) ANOVA was performed on percent preference for the bottle containing EtOH
and revealed no concentration effect, F{2, 52)=0.167, p=.847. A mixed 2 (Naltrexone: yes, no) x
2 (lPS: yes, no) x 2 (Concentration: 15% and 18%) ANOVA was performed on percent
preference for the bottle containing EtOH and revealed no concentration effect, F(1,26)=1.689,
p=.205. Therefore, the 5 concentrations (5%, 8%, 12%, 15%, and 18%) were collapsed into two

groups: IIlow" for concentrations below the home cage concentration of 13% and IIHigh" for
concentrations above the home cage concentration. These preference scores are plotted in
figure 8. A mixed 2 (Naltrexone: yes, no) x 2 (lPS: yes, no) x 2 (Concentration: low, high) ANOVA
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was performed on percent preference for the bottle containing EtOH. A main effect for
concentration was revealed, F(1, 26)=19.199, p<.001, .,2=.425. There was a significantly greater
preference for the "Iow" concentration (M=74.82, 5D=12.00) than the "high" concentration
(M=59.03, 5D=16.81). There was no Naltrexone X LPS X Concentration interaction, F(1,26}=.010,
p=.922. No other interactions were significant.
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Figure 8. Preference for the bottle containing EtOH during Individual tests

EtOH grams consumed. A mixed 2 (Naltrexone: yes, no) x 2 (LPS: yes, no) x 3
(Concentration: 5%, 8%, and 12%) ANOVA was performed on grams of EtOH and revealed no
concentration effect, F(2, 52}=.682, p=.510. A mixed 2 (Naltrexone: yes, no) x 2 (LPS: yes, no) x 2
(Concentration: 15% and 18%) ANOVA was performed on grams of EtOH and revealed no
concentration effect, F(1,26)=.021, p=.887. Therefore, 5 concentrations (5%, 8%, 12%,15%, and
18%) were collapsed into two groups: "Low" for concentrations below the home cage
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concentration of 13% and "High" for concentrations above the home cage concentration. The
grams of EtOH consumed are plotted in figure 9. A mixed 2 (Naltrexone: yes, no) x 2 (LPS: yes,
no) x 2 (Concentration: low, high) ANOVA was performed on the grams of EtOH consumed. This
2

ANOVA revealed a significant concentration X LPS interaction, F(l,26)=4.306, p=.048, 11 =.142.
Post-hoc independent samples t-tests revealed that the animals which received LPS (Low:
M=.32, 50=.12; High: M=.49, 50=.16) consumed significantly more grams of EtOH than the

animals which received saline (Low: M=.29, 50=.12; High: M=.38, 50=.12) only at high
concentrations, t(28)=2.15, p=.040. There was a significant main effect of concentration, F(l,
26)=35.492, p<.OOl. There was no Naltrexone x LPS x Concentration interaction, F(4,26)=.005,
p=.943.
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Figure 9. Grams of EtOH consumed during individual tests
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Discussion
In 2011, Blednov et al showed that a single injection of lPS increased the intake and
preference of EtOH in mice bred to be EtOH-preferring. Casachahua (2011) found this same
effect in long-Evans rats not bred specifically for EtOH preference, but this study also
addressed other questions not focused on EtOH intake and preference and included signtracking of EtOH in daily sessions. The present study attempted to replicate the lPS-induced

"

t
increase of EtOH intake and extend the study by examining the effects of Naltrexone on the lPS

t

effect. In the present study we did notobserve an lPS-induced increase in home-cage EtOH
preference over water. While initially there was a strong preference by all groups for the EtOH
bottle at lower EtOH concentrations, at 7% EtOH this preference drastically decreased in all
groups. When the EtOH concentration was reduced as low as 3%, there was no preference
recovery. It is unclear why the rats in the present study (regardless of lPS treatment) consumed

I

less EtOH in the home cages compared to the Casachahua study. One contributing factor may
be that all of the rats in the previous study had daily experience in a sign tracking procedure
where a bottle CS was paired with sucrose pellet UCSs and half of the rats had the additional
experience of consuming various concentrations of EtOH from the bottle CS.

In an attempt to induce EtOH intake again the intermittent availability of EtOH was
introduced. Previous studies have shown that the intermittent access to EtOH increases EtOH
intake in rodents (Rosenwasser et at, 2012; Simms et ai, 2008). In fact Simms and colleagues
(2008) found that long-Evans rats consumed more EtOH and had a higher preference for a 20%
EtOH solution when on a three-day-a-week intermittent schedule than for continuous access to
10% or 20% EtOH. In 2010, Simms and colleagues found that long-Evans rats acquire operant
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conditioned responding with a 20% EtOH reinforcer if tested while home-cage EtOH was
provided on an intermittent schedule but not on a daily schedule. Interestingly the
intermittency effect is not seen solely in EtOH intake, but sucrose as well (Martin & Timofeeva,
2010). By changing the schedule from daily EtOH exposure to a three-day-a-week schedule
EtOH intakes increased again and a preference for EtOH was re-established. Although the
original studies as well as some of the intermittent schedule studies had animals consuming
high levels of EtOH at least up to an 18% concentration (Blednov et aI., 2011; Casachahua,
2011; Simms et aI., 2008; Simms et al., 2010), most of the animals in the current study stopped
displaying a preference for the EtOH bottle at 13%. Therefore, the concentration was
maintained at this level while individual two-bottle preference tests were conducted for the
remainder of the experiment.

Previous literature does not delve into the mechanisms behind why intermittency
increases EtOH consumption. However, learning theory suggests several possibilities.
Habituation processes, for example, may modulate intake during intermittent access to EtOH.
According to Rankin and colleagues (2009) habituation is a decrease in a behavioral response to
a stimulus resulting from the repeated exposure to the stimulus. Although habituation is
traditionally thought of as an experimental paradigm for the study of non-associative learning,
it occurs in many situations outside of habituation procedures, even during motivated
behaviors such as feeding and operant responding (Rankin et aI., 2009). The novelty of the
EtOH induced increased consumption at the lowest concentrations, habituation could explain
why the animals reduced responding to the EtOH bottle when presented continuously.

J
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Habituation has several other characteristics associated with it. Another characteristic of
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habituation is spontaneous recovery which occurs after the response habituates, if the stimulus
is withheld, the response recovers when it is later reintroduced (Rankin et aI., 2009). By only
having access to the EtOH bottle three days a week, the rats began responding to the EtOH
bottle again each time it was reintroduced. When the animals began drinking from the EtOH
bottle to which they had become habituated they were exhibiting spontaneous recovery.

Additionally, the absence of the EtOH bottle may have allowed the rats to recover from
negative effects of EtOH which would decrease their intake time. Acute intoxicating effects of
EtOH in rats include loss of righting reflex, loss of coordination, and sedation (Caldwell et aI.,
2006),effects thatmay prevent the animals from consuming EtOH at least at the highest
concentrations used. This would lead to decreased consumption of EtOH while intoxicated.
However, if the animals were given time to recover from these effects, the next time the EtOH
bottle was presented, the animals would be able to reach and consume from the bottle.

Our attempt to increase EtOH intake by introducing an intermittent home-cage
exposure to EtOH was successful; however, once the rats were consuming the EtOH, an
interesting pattern emerged that differed from previous studies. While Blednov et al. (2011)
and Casachahua (2011) found that rodents injected with a single dose of LPS drank significantly
more than controls, the present study found that only the group treated with LPS and
naltrexone showed increase in intake of grams of EtOH during an intermittent EtOH availability
schedule. Casachahua (2011) used a sign-tracking procedure that this study did not utilize.
Perhaps this task prompted the LPS animals to drink more in their home cages. However, the
group of rats that received both naltrexone and LPS consumed significantly more EtOH than the
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other three groups. Interestingly, of the animals who received LPS, those that also received
naltrexone recovered faster from its effects as indicated from the recovery of body weight after
LPS treatment. This is not surprising. Lin et al (2005) found that naltrexone pretreatment
prevented sepsis in rats given a large dose of LPS (10 mg/kg). The rats which had been
pretreated had significant recovery of many of the effects including bradycardia,
vasoconstriction, and hypotension within six hours of administration; whereas, the control
animals did not. Wang et al (2005) found that post-treatment with naltrexone prevented liver
malfunction in mice after receiving an injection of LPS and D-galactosamine, a hormone which
damages the liver. Given these protective and recovery promoting effects, it makes sense that
the rats receiving naltrexone had a faster recovery rate, as measured by body weight. The
results of the present study suggest that naltrexone also affected the impact of LPS on
subsequent EtOH intake.

We had hypothesized that the naltrexone would possibly decrease the effect that LPS
had on EtOH drinking. LPS binds to the TLR4 on immune cells, while naltrexone blocks these
same receptors. The recovery effects of naltrexone could be a result of this partial blocking of
the TLR4 (Hutchinson et al., 2008). Because this is the same receptor to which LPS binds,
chronically blocking it could lead to a smaller immune response and faster recovery time
(Waetz & Wittfield, 2002). Just as we saw this faster recovery in bodyweight after LPS
treatment, presumably due to blocking the TLR4, we expected a reduced LPS effect on EtOH
intake and preference. However, we found the opposite; naltrexone interacted with LPS to
increase EtOH drinking in these animals. Naltrexone is not a selective antagonist of the TLR4; it
also antagonizes the opioid system (Lee et at, 1988). It may be that somehow the chronic

I
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antagonism of the opioid receptors in the brain along with the TLR4 in the immune system
interacted to create the increase in EtOH intake seen in these animals. We cannot rule out that
direct effects on the opiate receptors of the brain are at least partially responsible for the
results found in this study.

It is important to note that a LPS-induced increase in EtOH drinking was only seen in the
grams of EtOH consumed, not the preference of EtOH. This means that while these animals
consumed more EtOH, they also consumed more water. Greater absolute intake in EtOH
without a significant preference for EtOH may suggest that the some other mechanism is
driving EtOH intake other than a preference for EtOH over water. It is possible, for example,
that the initial "preference" for EtOH at the low concentrations is due to an increase in EtOH
intake unrelated to palatability (e.g., due to the novelty of the taste) but that with further
experience an increase in a true hedonic preference for the EtOH develops over water that is
observed even at the highest EtOH concentrations. Whereas a LPS-induced increase in intake
and preference was achieved in the previous study (Casachahua, 20ll), a significant increase in
absolute intake of EtOH was observed in the present study without a significant increase in
EtOH preference over water. It is pOSSible, for example, that the rats which consumed more
EtOH in this study were also drinking more water to counteract some effects of EtOH (e.g.,
washing the mouth of the taste of EtOH).

An important distinction in consumption is that of liking as opposed to wanting. Liking
in this study was measured as the preference of EtOH over water; whereas, grams of EtOH
consumed was the measure of wanting. Liking may be caused by the taste or subjective effects
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of the substance (that is, the palatability of the substance). Wanting, however, may develop
from a multitude of motivational factors such as caloric value, intermittent availability, or social
interaction (Berridge, 1996). Interestingly, liking and wanting have different pathways in the
br~in.

The preference for a substance is controlled by the opioid system; whereas, wanting is

mediated by the mesotelencephalic dopamine pathway (Berridge, 1996). Therefore, any longlasting effect of naltrexone on the opioid system would likely have decreased preference
(liking) rather than increase the intake of grams of EtOH (wanting). This makes it more likely
that the results seen in this study can be attributed to the combination of effects on the TLR4
from LPS and naltrexone.

The short-term individual tests were generally consistent with the pattern of results.
The graphs of these data show an apparent naltrexone x LPS interaction, suggesting that LPS
resulted in greater EtOH intake in Naltrexone-treated rats than in Saline-treated rats; however,
this interaction fell short of significance. One of the issues is a lack of power; each group only
had a maximum of eight rats. Nevertheless a significant LPS x EtOH concentration interaction
suggests that overall LPS did have an effect on EtOH intake, although not as robust as in the
prior study. However, this effect was only seen at concentrations higher than the home cage
concentration of 13%.

It is possible that LPS has a weaker effect on EtOH intake in rodents not bred for EtOH
preference, such as Long-Evans rats, compared to EtOH-preferring mice. Perhaps to have an LPS
effect there must be an initial high rate of EtOH intake as seen in the Blednov et al (2011) EtOH
preferring mice, or in rats with experience in the home cage and outside of the home cage, as
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in Casachahua (2011), or in rats exposed to intermittent EtOH presentations. Of these three
possibilities, the first procedure appears to be the most effective.

Blednov et al (2011) found that different genetic background of mice produced different
magnitudes of the LPS effect. They found the greatest difference in the strain bred to consume
high amounts of EtOH. Blednovet al (2011) also suggest that the effect of LPS on EtOH intake is
due to modulation of the TLR4. This is at least partially validated by Blednov et al (2012) finding
that C014 knockout mice had very low EtOH intake because C014 is a co-receptor of TLR4
(Abbas & Lichtman, 2005). Blednov et al (2011) suggest that because LPS cannot pass the
blood-brain barrier, the cytokines released from the peripheral immune cells affect the central
nervous system, leading to neuroinflammation. Long-term neuroinflammation is the most likely
cause of the increased EtOH consumption after LPS treatment. However, the results of the
present study suggests that antagonism of the TLR4 receptor on subsequent EtOH consumption
is complex, since repeated naltrexone treatment before and after an LPS injection appears to
have enhanced a weak LPS-induced increase in EtOH consumption.

This study leads to many possible future directions. Future studies should manipulate
the effects of environment changes on the LPS effect to understand why the results of this
study varied from Casachahua (2011). This study would attempt to replicate the present
findings but also manipulate experiences outside of the home cage. This can be achieved by
adding a group that is trained to sign-track a bottle with or without EtOH, while another group
has no such experience. This study only examined individual EtOH preference and consumption
after the home-cage concentration was maintained at 13%. Another change would be to give
f

32

\

the short-term preference tests repeatedly from the beginning of the study. This would also
determine if increases in the absolute intakes of EtOH appear before the development of a
preference or if preferences emerge before or simultaneous with increased intakes. That is, it
would be of interest to determine if immune system activation by lPS increases EtOH
consumption, which in turn results in the development of an EtOH preference, which then may
contribute to a path towards EtOH dependence.

In order to determine if the opioid system is involved in the escalation of intake by the
rats receiving both naltrexone and LPS, a future study should use dextro-naltrexone instead of
the standard levo-naltrexone. D-naltrexone is the mirror image of I-naltrexone, which causes
interesting effects (Hutchinson et aI., 2008). It is not used frequently because, unlike its left
handed brother, i~ does not antagonize the opioid system (Chatterjie, Sechzer, Lieberman &
Alexander, 1998). Therefore, it was not thought to be effective for use in treatment for
narcotics or alcohol. This would prevent the decrease in caloric intake and the decreased
palatability from being an issue in this study. However, it still binds to the TLR4 in the same
manner as I-naltrexone does (Hutchinson et al., 2008). This means that it would still suppress
the immune system.
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